Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 pandemic on tuberculosis control: an overview. Tropical Med Infect Dis. 2020;5(3):123.

Article  Google Scholar 

World Health Organization. Global tuberculosis report 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. 2022. Accessed 27 Oct 2022.

WHO Guidelines Approved by the Guidelines Review Committee. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization World Health Organization 2019;2019.

Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012;205(S2):S241–9.

Article  PubMed  Google Scholar 

Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study. BMC Public Health. 2011;11:696.

Article  PubMed  PubMed Central  Google Scholar 

Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 1973;4(2):94–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Das PK, Ganguly SB, Mandal BH. Sputum smear microscopy in tuberculosis: it is still relevant in the era of molecular diagnosis when seen from the public health perspective. Biomed Biotechnol Res J. 2019;3(2):77–9.

Article  Google Scholar 

van Zyl-Smit RN, Binder A, Meldau R, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS ONE. 2011;6(12): e28815.

Article  PubMed  PubMed Central  Google Scholar 

Goletti D, Arlehamn CSL, Scriba TJ, et al. Can we predict tuberculosis cure? What tools are available? Eur Respirat J 2018;52(5):1801089

Yong YK, Tan HY, Saeidi A, et al. Immune biomarkers for diagnosis and treatment monitoring of tuberculosis: current developments and future prospects. Front Microbiol. 2019;10:2789.

Article  PubMed  PubMed Central  Google Scholar 

Heyckendorf J, Georghiou SB, Frahm N, et al. Tuberculosis treatment monitoring and outcome measures: new interest and new strategies. Clin Microbiol Rev. 2022;35(3): e0022721.

Article  PubMed  Google Scholar 

Gilpin C, Kim SJ, Lumb R, Rieder HL, Van Deun A. Critical appraisal of current recommendations and practices for tuberculosis sputum smear microscopy. Int J Tuberculosis Lung Disease. 2007;11(9):946–52.

CAS  Google Scholar 

Maher D, Chaulet P, Spinaci S, Harries A, Stop TB Partnership. Treatment of tuberculosis: guidelines for national programmes. Centers for Disease Control and Prevention; 2003.

Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387–94.

Article  PubMed  PubMed Central  Google Scholar 

Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int J Tuberculosis Lung Dis. 2008;12(11):1226–34.

CAS  Google Scholar 

Desikan P. Sputum smear microscopy in tuberculosis: is it still relevant? Indian J Med Res. 2013;137(3):442–4.

PubMed  PubMed Central  Google Scholar 

Bahrmand AR, Velayati AA, Bakayev VV. Treatment monitoring and prevalence of drug resistance in tuberculosis patients in Tehran. Int J Tuberculosis Lung Dis. 2000;4(6):544–9.

CAS  Google Scholar 

Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect. 2012;18(7):711–7.

Article  CAS  PubMed  Google Scholar 

Diacon AH, van der Merwe L, Demers AM, von Groote-Bidlingmaier F, Venter A, Donald PR. Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens. Tuberculosis (Edinb). 2014;94(2):148–51.

Article  PubMed  Google Scholar 

Wallis RS, Peppard T, Hermann D. Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS ONE. 2015;10(4):e0125403.

Article  PubMed  PubMed Central  Google Scholar 

Ige OM, Oladokun RE. Time to sputum culture conversion and treatment outcome among the first cohort of multidrug resistant tuberculosis patients in a high burden country. Indian J Tuberc. 2018;65(4):322–8.

Article  CAS  PubMed  Google Scholar 

Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3(3):201–9.

Article  PubMed  PubMed Central  Google Scholar 

Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS ONE. 2013;8(5):e63840.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tierney DB, Franke MF, Becerra MC, et al. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoS ONE. 2014;9(9):e108035.

Article  PubMed  PubMed Central  Google Scholar 

Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respirat J. 2017;49(3):1601558.

Article  Google Scholar 

Chihota VN, Grant AD, Fielding K, et al. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberculosis Lung Dis. 2010;14(8):1024–31.

CAS  Google Scholar 

Panicker RO, Kalmady KS, Rajan J, Sabu MK. Automatic detection of tuberculosis bacilli from microscopic sputum smear images using deep learning methods. Biocybernetics Biomed Eng. 2018;38(3):691–9.

Article  Google Scholar 

Chang J, Arbeláez P, Switz N, et al. Automated tuberculosis diagnosis using fluorescence images from a mobile microscope. Med Image Comput Comput-Assisted Intervention. 2012;15(Pt 3):345–52.

CAS  Google Scholar 

Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570–81.

Article  PubMed  Google Scholar 

Cuevas LE, Al-Sonboli N, Lawson L, et al. LED fluorescence microscopy for the diagnosis of pulmonary tuberculosis: a multi-country cross-sectional evaluation. PLoS Med. 2011;8(7):e1001057.

Article  PubMed  PubMed Central  Google Scholar 

Datta S, Sherman JM, Bravard MA, Valencia T, Gilman RH, Evans CA. Clinical evaluation of tuberculosis viability microscopy for assessing treatment response. Clin Infect Dis. 2015;60(8):1186–95.

Article  PubMed  Google Scholar 

Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980;121(6):939–49.

CAS  PubMed  Google Scholar 

Paramasivan CN, Herbert D, Umapathy KC, Rahman F, Krishnamurthy PV, Prabhakar R. Early bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide in pulmonary tuberculosis patients. Indian J Med Res. 1994;100:1–4.

CAS  PubMed  Google Scholar 

Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397–405.

Article  CAS  PubMed  Google Scholar 

Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(8):2831–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med. 2001;1:2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanrahan CF, Theron G, Bassett J, et al. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respirat Crit Care Med. 2014;189(11):1426–34.

Article  Google Scholar 

Beynon F, Theron G, Respeito D, et al. Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa. Sci Rep. 2018;8(1):5201.

Article  PubMed  PubMed Central  Google Scholar 

Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013;1(6):462–70.

Article  CAS  PubMed  Google Scholar 

Pires MM, Pereira GR, Barbosa MS, et al. Association of Xpert MTB/RIF cycle threshold values with tuberculosis treatment outcomes. Lung. 2020;198(6):985–9.

Article  PubMed  Google Scholar 

Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM. Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur Respir J. 2012;39(5):1269–71.

Article  PubMed  Google Scholar 

Jayakumar A, Savic RM, Everett CK, et al. Xpert MTB/RIF assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine exposure. J Clin Microbiol. 2016;54(12):3028–33.

Article